IMW 2019 | PROMISE: findings and key considerations

Annie Cowan

Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, discusses the key considerations being made in the uptake of participants in the PROMISE trial (NCT03689595), the importance of screening high-risk individuals for myeloma precursor conditions and some preliminary findings at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video